Molecule
Copper is a copper-containing intrauterine device indicated for prevention of pregnancy in females of reproductive potential for up to 10 years. It is available as intrauterine systems. MedsAcross supplies Copper for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Paragard is indicated for prevention of pregnancy in females of reproductive potential for up to 10 years. Paragard is a copper-containing intrauterine system (IUS) indicated for prevention of pregnancy in females of reproductive potential for up to 10 years.
Source: US FDA prescribing information
Copper continuously released into the uterine cavity contributes to the contraceptive effectiveness of Paragard. Mechanism(s) by which copper enhances contraceptive efficacy include interference with sperm transport and fertilization of an egg, and possibly prevention of implantation.
Source: US FDA prescribing information
Insert a single Paragard at the fundus of the uterine cavity. Remove Paragard no later than 10 years from the date of insertion. Insert and remove Paragard only if you are a healthcare provider trained on these procedures. See the Full Prescribing Information for recommended timing of insertion preparation instructions, insertion procedures, postplacement management, and instructions on removing Paragard. Following the insertion, examine the patient after her first menses to confirm Paragard is still in place.
Source: US FDA prescribing information
The use of Paragard is contraindicated when one or more of the following conditions exist: Pregnancy or suspicion of pregnancy Abnormalities of the uterus resulting in distortion of the uterine cavity Acute pelvic inflammatory disease (PID) Postpartum endometritis or postabortal endometritis in the past 3 months Known or suspected uterine or cervical malignancy Uterine bleeding of unknown etiology Untreated acute cervicitis or vaginitis or other lower genital tract infection Conditions associated with increased susceptibility to pelvic infections Wilson’s disease A previously placed IUD or IUS that has not been removed Hypersensitivity to any component of Paragard including to copper or any of the trace elements present in the copper component of Paragard Pregnancy or suspicion of pregnancy.
Source: US FDA prescribing information
Ectopic Pregnancy: Promptly evaluate women who become pregnant for ectopic pregnancy while using Paragard. Risks with Intrauterine Pregnancy: Increased risk of spontaneous abortion, septic abortion, premature delivery, sepsis, septic shock and death if pregnancy occurs. Remove Paragard if pregnancy occurs with Paragard in place. Sepsis: Group A streptococcal infection has been reported, strict aseptic technique is essential during insertion. Pelvic Inflammatory Disease (PID) and Endometritis: Before using Paragard, consider the risks of PID and endometritis. Promptly assess and treat patients with signs and symptoms of PID. Embedment: Surgical removal may be necessary. Perforation: May reduce contraceptive effectiveness and require surgery. Risk is increased if inserted in lactating women and may be increased if inserted in women with fixed, retroverted uteri or noninvoluted uteri.
Source: US FDA prescribing information
The following serious adverse reactions are discussed elsewhere in the labeling: Ectopic pregnancy Intrauterine pregnancy Septic abortion Group A Streptococcal Sepsis (GAS) Pelvic Inflammatory Disease and Endometritis Embedment Perforation Expulsion Bleeding Pattern Alterations Adverse reactions reported in clinical trials include: anemia, backache, dysmenorrhea, dyspareunia, expulsion (complete or partial), prolonged menstrual flow, menstrual spotting, pain and cramping, and vaginitis. Table 2: Summary of Rates* (No. per 100 Subjects) by Year for Adverse Reactions Causing Discontinuation
Source: US FDA prescribing information
No drug-drug interaction or drug-herbal supplement interaction studies have been conducted with Paragard.
Source: US FDA prescribing information
Store at controlled room temperature: 59° to 86°F (15° to 30°C).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
2 presentations of Copper, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| ParaGard T 380A 313.4 mg intrauterine systemIntrauterine | CooperSurgical | US FDA | Available on request |
| Miudella 175 mm intrauterine systemIntrauterine | Organon | US FDA | Available on request |
2 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 15 November 1984 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 2 presentations of Copper and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 2 brand names for Copper, including Miudella, ParaGard T 380A.
Yes. The US FDA first approved Copper on 15 November 1984, according to Drugs@FDA.
No listed presentation of Copper is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.